Besponsa .25 mg/mL
inotuzumab ozogamicin · INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
Besponsa is a injection, powder, lyophilized, for solution containing inotuzumab ozogamicin at .25 mg/mL, taken intravenous. Manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc..
Key Facts
- Brand Name
- Besponsa
- Generic Name
- inotuzumab ozogamicin
- NDC Code (Product)
0008-0100- Manufacturer
- Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
- Strength
- .25 mg/mL
- Dosage Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761040
- Drug Class
- CD22-directed Immunoconjugate [EPC]
- Marketing Start
- 08/18/2017
Recall History
No Recall HistoryFrequently Asked Questions
What is Besponsa used for?
Besponsa contains inotuzumab ozogamicin. It is a injection, powder, lyophilized, for solution taken intravenous. Consult your doctor for specific uses.
Is Besponsa a controlled substance?
Besponsa is not classified as a controlled substance by the DEA.
What is the generic name for Besponsa?
The generic name for Besponsa is inotuzumab ozogamicin. There are no other listed brand versions of inotuzumab ozogamicin.
What is the NDC code for Besponsa .25 mg/mL?
The NDC (National Drug Code) for Besponsa .25 mg/mL is 0008-0100, listed by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc..
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)